Global Cholestatic Pruritus Market Size is projected to reach USD 33.8 Billion by 2035 | CAGR 5.28%

Global Cholestatic Pruritus Market Size is projected to reach USD 33.8 Billion by 2035 | CAGR 5.28% 

According to a research report published by Spherical Insights & Consulting, the Global Cholestatic Pruritus Market is expected to grow from USD 19.2 billion in 2024 to USD 33.8 billion by 2035, at a CAGR of 5.28% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Cholestatic Pruritus Market Size, Share, and COVID-19 Impact Analysis, By Therapeutic Class (Biologics, Small Molecule Inhibitors, Topical Agents, Systemic Corticosteroids, and Others), By Indication (Chronic Kidney Disease-Associated Pruritus (CKD-aP), Atopic Dermatitis, Psoriasis, Cholestatic Pruritus, and Other Dermatological Conditions), By Route of Administration (Injectable, Oral, Topical, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.    https://www.sphericalinsights.com/reports/cholestatic-pruritus-market        

The cholestatic pruritus market refers to the worldwide industry consist of treatments for severe, chronic itching caused by bile acid buildup from liver diseases like Primary Biliary Cholangitis (PBC) and Intrahepatic Cholestasis of Pregnancy (ICP). Cholestatic pruritus is characterized by typical intense itch on the palms and soles, worsening at night, and is treated with medications such as cholestyramine, rifampicin, or opiate antagonists. The prevalence of liver diseases, increased condition awareness, and advancements in both pharmacological and non-pharmacological therapies are the factors primarily driving the market. The increasing prevalence of chronic liver conditions, growth of hepatology specialty care, and an increasing emphasis on targeted therapies & expanding clinical pipeline are driving the market growth. On the contrary, diagnostic challenges, high treatment costs, and significant side effects of current therapies are challenging the market.

The biologics segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the therapeutic class, the cholestatic pruritus market is divided into biologics, small molecule inhibitors, topical agents, systemic corticosteroids, and others. Among these, the biologics segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Biologics used for treating cholestatic pruritus include monoclonal antibodies and novel targeted agents for reducing debilitating itch. Its increased efficacy in chronic immune-driven pruritus is driving the segmental market growth.

The CKD-aP segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the indication, the cholestatic pruritus market is divided into chronic kidney disease-associated pruritus CKD aP atopic dermatitis, psoriasis, cholestatic pruritus, and other dermatological conditions. Among these, the CKD  segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is estimated that CKD associated Pruritus impacts 67 of haemodialysis patients, with of patients reportedly being moderately to extremely bothered by CKD aP.  The high prevalence of ESRD is responsible for propelling the market in the CKD aP segment.

The injectables segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the route of administration, the cholestatic pruritus market is divided into injectable, oral, topical, and others. Among these, the injectables segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segment include naloxone which is administered via intravenous infusion to provide rapid, temporary relief, reducing opioidergic tone that contributes to the itching.

North America is expected to hold the majority share of the global cholestatic pruritus market during the forecast period.

North America is expected to hold the majority share of about 40.0% in the global cholestatic pruritus market during the forecast period. The United States is the dominant country in the North America cholestatic pruritus market, owing to an increasing ageing population, improved diagnostic rates, and the emergence of novel therapies. North America has a robust market ecosystem due to the high prevalence of conditions like PBC, PSC, and PFIC. Further, an increasing number of drug approvals for treating cholestatic pruritus contributes to escalating the cholestatic pruritus market.

Asia Pacific is anticipated to grow at the fastest pace of 13.9% CAGR in the global cholestatic pruritus market during the forecast period. China is the leading country in the Asia Pacific market, holding the dominant share, owing to the government investments and emphasis on advanced membrane technologies and municipal infrastructure upgrades. In the Asia Pacific cholestatic pruritus market, there is an increasing number of clinical research activities and an increasing need related to advanced nephropathy cases. Governments support for drug development also contributes to enhancing market growth.

Major vendors in the global cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., and Others.   

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In March 2026, Mirum Pharmaceuticals Inc. announced it had completed enrollment in  a  study evaluating maralixibat for teating cholestatic pruritus in patients aged  or older with rare cholestatic liver diseases, including biliary atresia.

• In February 2026, Mirum Pharmaceuticals, Inc., a leading rare disease company, announced that Health Canada has authorized the tablet formulation of LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome ALGS

• In September 2025, Medison and Ipsen announced that Health Canada has approved Bylvay odevixibat for the treatment of cholestatic pruritus in patients  months and older with Alagille Syndrome ALGS

• In March 2025, Mirum Pharmaceuticals, Inc. announced that its partner Takeda Pharmaceutical Company Limited, had received approval from the Japanese Ministry of Health Labour, and Welfare

• for LIVMARLI maralixibat oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome ALGS and Progressive Familial Intrahepatic Cholestasis PFIC in Japan.

• In March 2024, the Food and Drug Administration (FDA) approved Livmarli maralixibat for the treatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis PFIC

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the cholestatic pruritus market based on the below-mentioned segments:

Global Cholestatic Pruritus Market, By Therapeutic Class

• Biologics
• Small Molecule Inhibitors
• Topical Agents
• Systemic Corticosteroids
• Others

Global Cholestatic Pruritus Market, By Indication

• Chronic Kidney Disease-Associated Pruritus (CKD-aP)
• Atopic Dermatitis
• Psoriasis
• Cholestatic Pruritus
• Other Dermatological Conditions

Global Cholestatic Pruritus Market, By Route of Administration

• Injectable
• Oral
• Topical
• Others

 Global Cholestatic Pruritus Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter